7-硝基-1,2,3,4-四氢异喹啉 | 42923-79-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 7-硝基-1,2,3,4-四氢异喹啉
• 中文别名: 7-硝基-四氢异喹啉
• 英文名称: 7-nitro-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 1,2,3,4-tetrahydro-7-nitro-Isoquinoline
• CAS: 42923-79-5
• 化学式: C₉H₁₀N₂O₂
• mdl: MFCD04973400
• 分子量: 178.191
• InChiKey: YPRWYZSUBZXORL-UHFFFAOYSA-N

物化性质

• 沸点：
  319.6±42.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Nitro-1,2,3,4-tetrahydroisoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Nitro-1,2,3,4-tetrahydroisoquinoline
CAS number: 42923-79-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10N2O2
Molecular weight: 178.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-硝基-1,2,3,4-四氢异喹啉 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以gave 1,2,3,4-tetrahydroisoquinolin-7-amine as a pink solid in quantitative yield的产率得到7-氨基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  Bicyclic compounds with kinase inhibitory activity

  摘要：

  本发明提供了一种新颖的双环化合物，可用作蛋白激酶抑制剂。本发明还提供了包括本发明化合物的制药组合物以及使用该组合物治疗各种疾病的方法。

  公开号：

  US20070149533A1
• 作为产物：
  描述：

  1-(3,4-二氢-2(1H)-异喹啉基)-2,2,2-三氟乙烷酮 在 盐酸 、 硫酸 、 potassium nitrate 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 7-硝基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  N-（嘧啶-2-基）-1,2,3,4-四氢异喹啉-6-胺衍生物作为选择性Janus激酶2抑制剂治疗骨髓增生性肿瘤

  摘要：

  在这项研究中，我们描述了一系列的N-（嘧啶-2-基）-1,2,3,4-四氢异喹啉-6-胺衍生物作为选择性JAK2（Janus激酶2）抑制剂。通过基于先前报道的化合物18e的环化修饰，系统地研究结构与活性之间的关系，从而发现了高级衍生物13ac。化合物13ac对JAK2激酶，SET-2和Ba / F3 V617F细胞（JAK2 V617F突变的高表达）显示出极好的效价，IC 50值分别为3、11.7和41 nM。进一步的机理研究表明，化合物13ac可能下调细胞中JAK2激酶下游蛋白的磷酸化。在SET-2异种移植模型中，化合物13ac在激酶扫描中也显示出良好的选择性，并具有强大的体内抗肿瘤功效，并具有82.3％的肿瘤生长抑制率。此外，13ac显着改善了Ba / F3-JAK2 V617F同种异体移植模型的疾病症状，脾脏重量正常化率为77.1％，比鲁索替尼更有效。

  DOI：

  10.1021/acs.jmedchem.0c01488

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Photocatalyzed Csp³–Csp³ cross-dehydrogenative coupling of <i>N</i>-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones
  作者：Na-Ri-Mei Ao、Xue-Qing Zhu、Chun-Xin Zhao、Ya-Ru Gao、Yong-Qiang Wang

  DOI：10.1039/d1ob00527h

  日期：——

  A novel photocatalyzed cross-dehydrogenative coupling reaction of N-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones has been developed. This research provides an easy access to a variety of C1-substituted tetrahydroisoquinolines, which can be further transformed into benzo[a]-quinolizine-2-ones, the skeletons of natural products with a wide range of biological activities. The load of the photocatalyst

  开发了一种新型光催化N -Boc-四氢异喹啉与 α,β-不饱和酮的交叉脱氢偶联反应。这项研究提供了一种容易获得各种 C1 取代的四氢异喹啉的方法，这些四氢异喹啉可以进一步转化为具有广泛生物活性的天然产物骨架苯并[ a ]-quinolizine-2-ones。光催化剂的负载量低，氧化剂便宜且毒性较小。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Non-Peptide Glycoprotein IIb/IIIa Antagonists. 11. Design and <i>in Vivo</i> Evaluation of 3,4-Dihydro-1(1<i>H</i>)-isoquinolinone-Based Antagonists and Ethyl Ester Prodrugs
  作者：John H. Hutchinson、Jacquelynn J. Cook、Karen M. Brashear、Michael J. Breslin、Joan D. Glass、Robert J. Gould、Wasyl Halczenko、Marie A. Holahan、Robert J. Lynch、Gary R. Sitko、Maria T. Stranieri、George D. Hartman

  DOI：10.1021/jm9604787

  日期：1996.1.1

  The structure-activity relationship of a series of orally active glycoprotein IIb/IIIa antagonists containing a nitrogen heterocycle grafted onto a 3,4-dihydro-1 (1H)-isoquinolinone core is described. These compounds are structurally novel analogs of the progenitor compound 1 (L-734,217,[[3(R)-[2-(piperidin-4-yl)ethyl]-2-oxopiperidinyl ]acetyl]-3(R)- methyl-beta-alanine) in which the lactam chiral

  描述了一系列口服活性糖蛋白IIb / IIIa拮抗剂的结构-活性关系，这些拮抗剂包含接枝到3,4-二氢-1（1H）-异喹啉酮核心上的氮杂环。这些化合物是祖细胞化合物1（L-734,217，[[3（R）-[2-（哌啶丁-4-基）乙基] -2-氧代哌啶基]乙酰基] -3（R）-甲基- β-丙氨酸），其中内酰胺手性中心已被去除。发现4-哌嗪基-和4-哌啶基-取代的3,4-二氢-1（1H）-异喹啉酮是体外效价的最佳选择。另外，用最有效的3-吡啶基和3-乙炔基类似物取代β-氨基酸的3-位增强了效力。试图改善这些化合物的体内特性的尝试集中在物理性质的改变上。制备酯前药以增加亲脂性并去除拮抗剂的两性离子性质。前药方法与芳基哌嗪末端（pKa =约9.0）结合，可提供中等碱性和相对非极性的化合物。酸N-[[[7-（哌嗪-1-基）-3,4-二氢-1（1H）-氧代异喹啉-2-基]乙酰基] -3（S）-乙炔基-β-丙氨酸，6d（L
• Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
  申请人：N30 Pharmaceuticals, Inc.

  公开号：US09138427B2

  公开（公告）日：2015-09-22

  The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

  本发明涉及S-亚硝基谷胱甘肽还原酶（GSNOR）的抑制剂，包括这种GSNOR抑制剂的药物组合物，以及制备和使用这些药物的方法。